Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Surgical Devices
scibase.se

See what CB Insights has to offer

Founded Year

1998

Stage

IPO | IPO

Date of IPO

6/2/2015

About SciBase

SciBase is a medical technology company that develops instruments for the detection of skin cancer. The Nevisense product can detect malignant melanoma, the most dangerous form of skin cancer, directly on the skin without needing to cut away suspect moles. The product is based on comprehensive research and SciBase has conducted the largest study to date on the detection of malignant melanoma, in which Nevisense achieved excellent results.

SciBase Headquarter Location

Kammakargatan 22

Stockholm, SE-111 40,

Sweden

Latest SciBase News

New clinical study shows Nevisense potential for assessment of Skin Barrier and Atopic Dermatitis

Apr 12, 2021

A A STOCKHOLM, April 12, 2021 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the publication of a new clinical study supporting SciBase's strategy to develop multiple clinical applications for the Nevisense and Nevisense Go platforms. The study is from the Swiss institute of Allergy and Asthma Research (SIAF) and has been published in the European Journal of Allergy and Clinical Immunology (Allergy). In the study Nevisense was used to assess the skin barrier of patients with atopic dermatitis (AD) and could accurately detect signs of atopic dermatitis even on unaffected skin. The Nevisense measurement also correlated with relevant biomarkers for atopic dermatitis. SIAF, based in Davos, is a world leader within applied allergy and asthma research. SIAF is headed by Director Cezmi Akdis, who is also Professor of the University of Zurich Medical Faculty and one of the directors of the Christine Kühne Center for Allergy Research and Education. Professor Akdis said, "Personalized and precision medicine is becoming one of the most exciting areas in all of medicine. Our research group has proposed the "epithelial barrier hypothesis", which asserts that defective epithelial skin barriers are the main reason for the initiation and increase of allergic and autoimmune conditions such as asthma, atopic dermatitis and inflammatory bowel disease. Furthermore, leakiness of the gut epithelium is also implicated in conditions such as diabetes, obesity, multiple sclerosis, rheumatoid arthritis and others. Moreover, distant microinflammatory responses due to a 'leaky gut' and microbiome changes are suspected in Alzheimer's disease, Parkinson's disease, chronic depression and autism spectrum disorders. Defective skin barrier is an important part of the "epithelial barrier hypothesis". Atopic dermatitis alone affects more than 10% of infants, and represents a huge health and socioeconomic burden. Skin barrier assessment shows potential to be clinically useful for early prediction of disease development, improved diagnosis, disease follow-up and therapy evaluation. This study shows that the Nevisense method can directly assess the status of epithelial barrier using electrical impedance spectroscopy (EIS). EIS was able to assess epithelial skin barrier integrity, differentiate between patients and controls without AD and characterize lesional and non-lesional skin of patients. EIS also showed a significant correlation with biomarkers associated with inflammatory pathways that may affect the skin barrier. Furthermore, copy numbers of filaggrin, an essential skin barrier molecule significantly correlated with EIS on non-lesional skin of patients. These findings that are presented in the article strongly indicates that Nevisense and the EIS method is a useful tool to detect skin barrier dysfunction.' SciBase CEO Simon Grant commented, "This is an exciting new application area for SciBase, and one where we have unique advantages. Barrier-related diseases are widespread, and assessment of the barrier can help better understand and treat patients. The study illustrates the potential for Nevisense to become a valuable tool for clinicians within AD and other epithelial barrier-related diseases. We see a number of applications with broad market potential, and we are working with SIAF and others to develop clinical products. For SciBase this an important milestone in our strategy to develop multiple clinical applications using our unique technology platform." The study can be found here : https://onlinelibrary.wiley.com/doi/10.1111/all.14842?af=R. For more information please contact: Simon Grant, CEO SciBase

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing SciBase

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SciBase is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

295 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA

SciBase Patents

SciBase has filed 4 patents.

The 3 most popular patent topics include:

  • Epidermal nevi, neoplasms, cysts
  • Immunology
  • Organ transplantation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/14/2005

5/2/2017

Epidermal nevi, neoplasms, cysts, Skin cancer survivors, Oncology, Oral mucosal pathology, Melanoma

Grant

Application Date

12/14/2005

Grant Date

5/2/2017

Title

Related Topics

Epidermal nevi, neoplasms, cysts, Skin cancer survivors, Oncology, Oral mucosal pathology, Melanoma

Status

Grant

SciBase Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

SciBase Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.